关于治疗阿片类药物引起的便秘的建议 - - 如何提高临床实践中的可用性
Tina Okdahl1, Anton Emmanuel2, Bart Morlion3
1Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Expert review of gastroenterology & hepatology
|October 12, 2023
概括
阿片类药物诱导的便秘没有得到充分的治疗. 简化,以行为为导向的建议,用于管理阿片类药物诱导的便秘,提供了更好的可用性,并可以提高患者的护理.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿片类药物引起的便秘 (OIC) 是阿片类药物治疗的常见且往往未得到充分治疗的副作用.
- 现有的OIC管理临床指南复杂且未得到充分利用,导致患者的治疗结果低于最佳.
研究的目的:
- 引入OIC的概念,并审查当前的管理准则.
- 根据指导方针综合和最佳设计原则,为OIC管理提出简化,以行为为导向的建议.
主要方法:
- 进行了OIC当前指导方针的综合.
- 应用了最佳指南设计理论的原则来简化建议.
- 拟议的简化建议在初级保健机构中得到了可用性和效益的验证.
主要成果:
- 制定了OIC管理的简化建议.
- 在初级保健中的验证证实了简化方法的可信度,清晰度,相关性,可用性和整体效益.
结论:
- 由于复杂的指导方针,目前的OIC管理往往是不够的.
- 简化,验证的建议有可能得到更广泛的采用,并改善OIC患者护理.
相关概念视频
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
215
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
215
Drugs for Treatment of Constipation-Predominant IBS
183
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
183
Drugs for Treatment of Diarrhea-Predominant IBS
188
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
188
Irritable Bowel Syndrome III: Medical and Nursing Management
217
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
217
Opioid Analgesics: Synthetic and Semisynthetic Opioids
311
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
311
Analgesia and Pain Management
636
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
636


